Dasatinib Monohydrate: Multitargeted ABL Kinase Inhibitor for Ph+ Leukemia & Tumor Microenvironment Research

Executive Summary: Dasatinib Monohydrate (BMS-354825) is a clinically approved multitargeted ATP-competitive kinase inhibitor with strong activity against ABL and SRC kinases (IC₅₀ of 0.55 nM for Src and 3.0 nM for Bcr-Abl) [APExBIO, Product Page]. It potently inhibits both wild-type and imatinib-resistant BCR-ABL isoforms, thus serving as a cornerstone in chronic myeloid leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) research [Shapira-Netanelov et al., 2025]. In advanced assembloid models, Dasatinib's performance enables robust investigation of tumor-stroma interactions and mechanisms of drug resistance. Its physicochemical properties—molecular weight 506.02, formula C₂₂H₂₈ClN₇O₃S, soluble at ≥25.3 mg/mL in DMSO—make it compatible with diverse experimental setups. The compound is distributed by APExBIO and has been FDA-approved since 2006 for Ph+ leukemias.

Biological Rationale

Dasatinib Monohydrate was developed to address limitations in single-target kinase inhibitors, particularly for patients with BCR-ABL mutations conferring resistance to first-generation drugs such as imatinib. The compound targets multiple tyrosine kinases, including ABL, SRC, KIT, and PDGFR, which are implicated in leukemogenesis, solid tumor progression, and therapy resistance [Shapira-Netanelov et al., 2025]. This multitargeted approach is critical for suppressing compensatory signaling pathways that drive disease persistence in CML and Ph+ ALL. Additionally, Dasatinib's broad kinase inhibition profile enables the study of kinase crosstalk and resistance mechanisms in complex tumor microenvironments, particularly when using advanced assembloid models that recapitulate stromal heterogeneity [Dasatinib in Next-Generation Tumor Microenvir.].

Mechanism of Action of Dasatinib Monohydrate

Dasatinib Monohydrate acts as a potent ATP-competitive inhibitor of several tyrosine kinases. Its primary targets are:

• BCR-ABL: Inhibits both nonmutated and imatinib-resistant isoforms, blocking the constitutive kinase activity responsible for uncontrolled proliferation in Ph+ leukemias.
• SRC Family Kinases: Inhibits Src, Lck, Yes, and Fyn kinases (IC₅₀ for Src: 0.55 nM), modulating cell adhesion, migration, and survival pathways.
• KIT and PDGFR: Inhibits receptor tyrosine kinases involved in hematological malignancies and certain solid tumors.

Dasatinib binds to the active and inactive conformations of its targets, contributing to its high potency and efficacy against kinase domain mutants. By blocking these kinases, Dasatinib disrupts downstream signaling pathways (e.g., STAT5, PI3K/AKT, RAS/RAF/MEK/ERK), inducing apoptosis and reducing proliferation in cancer cells. This broad mechanism makes it suitable for studying both on-target and off-target effects in preclinical models.

Evidence & Benchmarks

• Dasatinib Monohydrate exhibits an IC₅₀ of 0.55 nM for Src kinase and 3.0 nM for Bcr-Abl kinase, demonstrating high potency in biochemical assays (APExBIO, product page).
• In vitro, Dasatinib demonstrates antiproliferative effects across hematological and solid tumor cell lines at nanomolar concentrations (Shapira-Netanelov et al., 2025, DOI).
• In vivo mouse models of BCR-ABL-driven disease show significant reduction in disease progression and bioluminescent activity upon Dasatinib treatment (Shapira-Netanelov et al., 2025, DOI).
• Dasatinib maintains efficacy against BCR-ABL isoforms harboring imatinib resistance mutations, unlike first-generation inhibitors (APExBIO, product page).
• Assembloid models incorporating stromal cell subpopulations reveal that Dasatinib’s drug response profile can be modulated by microenvironmental context, providing insights into drug resistance mechanisms (Shapira-Netanelov et al., 2025, DOI).

Applications, Limits & Misconceptions

Dasatinib Monohydrate is widely used in translational oncology for:

• Modeling drug resistance in CML and Ph+ ALL, including imatinib-resistant variants.
• Dissecting kinase signaling pathways in both 2D and 3D cell culture systems.
• Studying tumor-stroma interactions using assembloid models that mimic patient-specific microenvironments.
• Screening for combinatorial therapies and resistance mechanisms in solid and hematological malignancies.

Compared to earlier articles such as "Dasatinib Monohydrate in Next-Generation Tumor Microenvir...", which introduces the role of Dasatinib in advanced tumor models, this article provides a more granular enumeration of quantitative potency, resistance profiles, and use in assembloid platforms. For a detailed mechanistic exploration of NET formation and vascular effects, see "Dasatinib Monohydrate: Unraveling NET Formation in CML wi..."; this present article focuses instead on kinase inhibition benchmarks and microenvironmental research. For implementation and optimal handling, refer to "Dasatinib Monohydrate: Multitargeted Tyrosine Kinase Inhi..."—the current review extends these workflows to assembloid systems.

Common Pitfalls or Misconceptions

• Dasatinib Monohydrate is insoluble in ethanol and water; DMSO (≥25.3 mg/mL) is required for stock preparation (APExBIO, product page).
• Short-term solution use is recommended; prolonged storage at room temperature or repeated freeze-thaw cycles may compromise stability.
• Not all kinase-driven tumors respond equally; efficacy in solid tumors may be microenvironment-dependent, as shown in assembloid models (Shapira-Netanelov et al., 2025).
• Dasatinib should not be conflated with unrelated tyrosine kinase inhibitors; its multitargeted profile is key to its unique applications.
• Clinical dosages and in vitro concentrations are not interchangeable; always calibrate for model relevance.

Workflow Integration & Parameters

Dasatinib Monohydrate (SKU B5954) from APExBIO is provided as a solid, with a molecular weight of 506.02 and the formula C₂₂H₂₈ClN₇O₃S. For in vitro studies, dissolve in DMSO to ≥25.3 mg/mL. It is insoluble in ethanol and water. Store at -20°C; for best results, prepare fresh solutions for each experiment. In assembloid workflows, apply Dasatinib at nanomolar concentrations (commonly 1–100 nM) to cell cultures or organoid co-cultures, monitoring cell viability, apoptosis, and kinase signaling endpoints. For in vivo murine studies, dosing regimens must be adjusted per body weight and route of administration as per published protocols. Always include vehicle-only controls and confirm compound integrity via HPLC or equivalent methods.

Conclusion & Outlook

Dasatinib Monohydrate remains a gold-standard multitargeted kinase inhibitor for both basic and translational research in CML, Ph+ ALL, and tumor microenvironment studies. Its robust inhibition of ABL, SRC, KIT, and PDGFR kinases, combined with proven efficacy against imatinib-resistant mutations and microenvironmental adaptability in assembloid systems, positions it as an indispensable tool for oncology research. Ongoing advances in organoid and assembloid technologies will further clarify Dasatinib's role in personalized medicine and resistance mechanism discovery. For ordering and specification details, visit the Dasatinib Monohydrate product page at APExBIO.